POLIPI NASALI - Mepolizumab ripristina le alterazioni del tessuto nasale e migliora la respirazione

CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS IN AN ALL-ITALIAN STUDY, MEPOLIZUMAB DEMONSTRATES RESTORATION OF NASAL TISSUE ALTERATIONS An all-Italian study by Professor Matucci's group was presented in Milan. The study evaluated the efficacy of mepolizumab on nasal polyps in patients with chronic rhinosinusitis with nasal polyposis, a condition associated with the excessive presence of inflammatory eosinophils. The study demonstrated that mepolizumab, a monoclonal antibody directed against interleukin 5 developed by GSK, not only achieved symptom control but also restored nasal tissue alterations. This is important news for all patients who live daily with a condition that severely impacts their quality of life. Restoring the structure of the nasal mucosa to normal is one of the objectives achieved by the study, opening up the prospects for more effective and targeted treatments. The study results are particularly significant because they demonstrated that mepolizumab is able to preserve "good" eosinophils and inhibit pro-inflammatory ones. These results were demonstrated not only in the blood but also in the restoration of nasal tissue. The study results open new perspectives for patients with complex, often associated conditions, such as rhinosinusitis with nasal polyposis and asthma. However, early intervention is important to block the inflammatory cascade, and biomarkers for type 2 inflammation currently play a central role in diagnosis. The study data also demonstrate that reducing "bad" eosinophils and maintaining the "good" ones not only improves breathing and smell but also reduces the number of surgical procedures, thus improving not only the prognosis but also the quality of life of patients. Chronic rhinosinusitis with nasal polyposis has a significant impact on patients' quality of life. The needs are both clinical and social, and it is important that research finds increasingly effective solutions to reduce symptoms and improve daily life. The mepolizumab study demonstrates how scientific research is essential to finding new solutions that can improve prognosis and quality of life. The increasingly in-depth understanding of immunological and inflammatory mechanisms now allows us to talk about clinical remission, an important goal for all patients. The mepolizumab study was presented to us by: Andrea Matucci, Medical Director of the Immunoallergology Department, Careggi University Hospital, Florence Alessandra Vultaggio, Associate Professor of Allergology and Clinical Immunology, Careggi University Hospital, Florence Luciano Cattani, President of the Severe Asthma Association Sara De Grazia, Medical Director of the GSK Therapeutic Area